Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Pfizer keeps declining, but it is not the only pandemic player to suffer.
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.